Paper41525014
Comparison of activated and 4-factor prothrombin complex concentrates for reversal of apixaban- and rivaroxaban-associated major bleeding.
Crawley RM and 1 other. J Thromb Thrombolysis, 2026. Cited by 3 papers, by iCite.
Cite this record
ConductScience Library. Comparison of activated and 4-factor prothrombin complex concentrates for reversal of apixaban- and rivaroxaban-associated major bleeding. Papers, record 41525014. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/41525014
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Comparison of activated and 4-factor prothrombin complex concentrates for reversal of apixaban- and rivaroxaban-associated major bleeding.
- PubMed
Topics12
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Blood Coagulation Factors | Major topic |
| Pyridones | Major topic |
| Rivaroxaban | Major topic |
| Hemorrhage | Major topic |
| Pyrazoles | Major topic |
| Factor Xa Inhibitors | Major topic |
| Humans | |
| Female | |
| Male | |
| Retrospective Studies | |
| Aged | |
| Middle Aged |
Source PubMed
References20
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 28835439 | Management of rivaroxaban- or apixaban-associated major bleeding with prothrombin complex concentrates: a cohort study. | Blood | 2017 | https://conductscience.org/library/papers/28835439 | PubMed |
| 2 | 16630353 | Thrombin generation by activated factor VII on platelet activated by different agonists. Extending the cell-based model of hemostasis. | Thromb J | 2006 | https://conductscience.org/library/papers/16630353 | PubMed |
| 3 | 24529498 | Reversal of rivaroxaban-induced anticoagulation with prothrombin complex concentrate, activated prothrombin complex concentrate and recombinant activated factor VII in vitro. | Thromb Res | 2014 | https://conductscience.org/library/papers/24529498 | PubMed |
| 4 | 32264698 | Factor Xa Inhibitor-Related Intracranial Hemorrhage: Results From a Multicenter, Observational Cohort Receiving Prothrombin Complex Concentrates. | Circulation | 2020 | https://conductscience.org/library/papers/32264698 | PubMed |
| 5 | 24391389 | Activated prothrombin complex concentrates for the reversal of anticoagulant-associated coagulopathy. | P T | 2013 | https://conductscience.org/library/papers/24391389 | PubMed |
| 6 | 11434702 | A cell-based model of hemostasis. | Thromb Haemost | 2001 | https://conductscience.org/library/papers/11434702 | PubMed |
| 7 | 38749032 | Andexanet for Factor Xa Inhibitor-Associated Acute Intracerebral Hemorrhage. | N Engl J Med | 2024 | https://conductscience.org/library/papers/38749032 | PubMed |
| 8 | 32500220 | Treatment of adults with intracranial hemorrhage on apixaban or rivaroxaban with prothrombin complex concentrate products. | J Thromb Thrombolysis | 2021 | https://conductscience.org/library/papers/32500220 | PubMed |
| 9 | 27573206 | Andexanet Alfa for Acute Major Bleeding Associated with Factor Xa Inhibitors. | N Engl J Med | 2016 | https://conductscience.org/library/papers/27573206 | PubMed |
| 10 | 35579034 | 2022 Guideline for the Management of Patients With Spontaneous Intracerebral Hemorrhage: A Guideline From the American Heart Association/American Stroke Association. | Stroke | 2022 | https://conductscience.org/library/papers/35579034 | PubMed |
| 11 | 37063756 | Four-factor prothrombin complex concentrate for the treatment of oral factor Xa inhibitor-associated bleeding: a meta-analysis of fixed versus variable dosing. | Res Pract Thromb Haemost | 2023 | https://conductscience.org/library/papers/37063756 | PubMed |
| 12 | 26391431 | Assessment of effectiveness of major bleeding management: proposed definitions for effective hemostasis: communication from the SSC of the ISTH. | J Thromb Haemost | 2016 | https://conductscience.org/library/papers/26391431 | PubMed |
| 13 | 34060371 | Investigation of the Optimal Dose aPCC in Reversing the Effect of Factor Xa Inhibitors-An In Vitro Study. | Clin Appl Thromb Hemost | 2021 | https://conductscience.org/library/papers/34060371 | PubMed |
| 14 | 32680646 | 2020 ACC Expert Consensus Decision Pathway on Management of Bleeding in Patients on Oral Anticoagulants: A Report of the American College of Cardiology Solution Set Oversight Committee. | J Am Coll Cardiol | 2020 | https://conductscience.org/library/papers/32680646 | PubMed |
| 15 | 11382723 | Ability of recombinant factor VIIa to generate thrombin during inhibition of tissue factor in human subjects. | Circulation | 2001 | https://conductscience.org/library/papers/11382723 | PubMed |
| 16 | 30046673 | The reversal effect of prothrombin complex concentrate (PCC), activated PCC and recombinant activated factor VII in apixaban-treated patients in vitro. | Res Pract Thromb Haemost | 2017 | https://conductscience.org/library/papers/30046673 | PubMed |
| 17 | 30476716 | Effect of low and moderate dose FEIBA to reverse major bleeding in patients on direct oral anticoagulants. | Thromb Res | 2019 | https://conductscience.org/library/papers/30476716 | PubMed |
| 18 | 24315724 | Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials. | Lancet | 2014 | https://conductscience.org/library/papers/24315724 | PubMed |
| 19 | 15842354 | Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients. | J Thromb Haemost | 2005 | https://conductscience.org/library/papers/15842354 | PubMed |
| 20 | 28239301 | The reversal effect of prothrombin complex concentrate (PCC), activated PCC and recombinant activated factor VII against anticoagulation of Xa inhibitor. | Thromb J | 2017 | https://conductscience.org/library/papers/28239301 | PubMed |
Cited by3
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 3 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42026420 | Personalised Antithrombotic Strategies in Diverse Clinical Populations. | J Thromb Thrombolysis | 2026 | https://conductscience.org/library/papers/42026420 | PubMed |
| 41976898 | Anticoagulation Stewardship Program in the DOAC Era. | J Clin Med | 2026 | https://conductscience.org/library/papers/41976898 | PubMed |
| 41975035 | Apixaban Overdose with Massive Bleeding and Anti-Xa Levels. | J Med Toxicol | 2026 | https://conductscience.org/library/papers/41975035 | PubMed |
Genes1
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes |
|---|---|---|---|
| F7 | 2155 | PubTator's text mining | https://conductscience.org/library/genes/2155 |
Source NCBI Gene
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/41525014
GET https://conductscience.org/api/papers/v1/41525014/authors